Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
The FDA has approved Zelboraf and Roche's companion diagnostic test for BRAF V600E mutation-positive metastatic melanoma. The joint approval is the first example of co-development and demonstrates the movement toward personalized cancer therapy, and Zelboraf's impressive efficacy data and the availability of a test will ensure rapid uptake.
Published By Datamonitor
|
18 Aug 2011 |
|
CommentWire
|
Vertex Pharmaceuticals' novel cystic fibrosis treatment VX-770 has demonstrated strong efficacy in a Phase III trial, meeting the primary endpoint and key secondary endpoints. VX-770 targets the underlying cause of the disease, and, if approved, would offer a novel treatment approach.
Published By Datamonitor
|
25 Feb 2011 |
|
CommentWire
|
Additional drug safety responsibilities could be placed on pharmaceutical companies with the introduction of a new US bill in the Senate. The bill, which comes in the wake of record product recalls, aims to strengthen manufacturing standards and better equip the FDA to oversee the pharmaceutical supply chain. However, if passed, the legislation would create considerable costs for drug makers.
Published By Datamonitor
|
10 Aug 2010 |
|
CommentWire
|
Although the FDA's complete response letter for Cimzia in rheumatoid arthritis will delay its US approval, Datamonitor believes UCB has the experience to handle the setback and the drug may still reach the market by the second half of 2009. Ultimately however, the delay will not be a major impediment as extensive uptake is not expected at launch due to poor differentiation in a mature drug class.
Published By Datamonitor
|
07 Jan 2009 |
|
CommentWire
|
A Datamonitor report has identified that the leading pharmaceutical and biotech companies face a major slowdown in sales growth out to 2014, primarily a result of the imminent patent expiries facing many blockbusters and the subsequent threat from generics. Prescription sales are expected to rise at a compound annual growth rate of just 1.2% over 2008-14, compared to a historical rate of 10.5%.
Published By Datamonitor
|
01 Mar 2010 |
|
Expert View
|
On May 2, 2011, Teva announced that it was to acquire US-based Cephalon for $6.8bn. The consolidation of Cephalon will accelerate Teva's strategy of an increased presence in the branded pharmaceutical market. Given that Cephalon's pipeline is heavily focused on oncology, an area in which Teva has no major branded presence, the deal will also prompt future therapeutic diversification.
Published By Datamonitor
|
18 May 2011 |
|
CommentWire
|
Encouraged by a partnership that has to date been successful, Millennium has invested further into Seattle Genetics' antibody-drug conjugate technology. As the wait for the first commercially successful antibody-drug conjugate therapeutic continues, pharmaceutical players are actively populating their pipelines with this innovative monoclonal antibody class.
Published By Datamonitor
|
17 Mar 2011 |
|
Expert View
|
The FDA has recommended accelerated approval for Adcetris for relapsed/refractory Hodgkin's lymphoma and relapsed/refractory systemic anaplastic large cell lymphoma. Treatment options for these indications are limited, and the advisory panels were unanimous in backing Adcetris's approval. Commercial success for the drug could attract further investment in antibody-drug conjugate technology.
Published By Datamonitor
|
15 Jul 2011 |
|
CommentWire
|
Seattle Genetics and Millennium: the Takeda Oncology Company have announced encouraging results from a Phase II trial of brentuximab vedotin in relapsed or refractory Hodgkin's lymphoma. Full results of the trial are yet to be published, but the candidate looks set to become the first immunotherapy approved for the disease.
Published By Datamonitor
|
29 Sep 2010 |
|
CommentWire
|
Sanofi and Genzyme have presented additional data analysis demonstrating Lemtrada's superiority over Rebif in reducing disability in MS. However, due to Lemtrada's potential to lead to the development of autoimmune adverse events, Datamonitor expects that the drug will be used at later lines of therapy and in patients with severe forms of MS.
Published By Datamonitor
|
30 Apr 2012 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.